GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.
To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-united-states-drug-forecast-and-market-analysis-to-2022-report.html
GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.
GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.
Scope
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.
To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in the US
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 15
3.3 Prognosis 16
4 Disease Management 17
4.1 Meningococcal Immunization Policy 18
4.2 US 20
4.2.1 Meningococcal Immunization Recommendations and Policies 20
4.2.2 Clinical Practice 22
To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Blog: http://dynamicmarketresearch.blogspot.com/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
To Browse a Full Report with TOC: http://www.researchmoz.us/pharmapoint-meningococcal-vaccines-united-states-drug-forecast-and-market-analysis-to-2022-report.html
GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.
GlobalData expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.
Scope
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.
To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in the US
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 15
3.3 Prognosis 16
4 Disease Management 17
4.1 Meningococcal Immunization Policy 18
4.2 US 20
4.2.1 Meningococcal Immunization Recommendations and Policies 20
4.2.2 Clinical Practice 22
To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=170311
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Blog: http://dynamicmarketresearch.blogspot.com/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
No comments:
Post a Comment